| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8648037 | ABBVIE INC | Macrocyclic proline derived HCV serine protease inhibitors |
Jan, 2032
(8 years from now) | |
| US8937150 | ABBVIE INC | Anti-viral compounds |
May, 2032
(8 years from now) | |
| USRE48923 | ABBVIE INC | Crystal forms |
May, 2035
(11 years from now) | |
| US9321807 | ABBVIE INC | Crystal forms |
Jun, 2035
(11 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10028937 | ABBVIE INC | Anti-viral compounds |
Jun, 2030
(6 years from now) | |
| US10039754 | ABBVIE INC | Anti-viral compounds |
Jun, 2030
(6 years from now) | |
| US9586978 | ABBVIE INC | Anti-viral compounds |
Nov, 2030
(7 years from now) | |
|
US10028937 (Pediatric) | ABBVIE INC | Anti-viral compounds |
Dec, 2030
(7 years from now) | |
|
US10039754 (Pediatric) | ABBVIE INC | Anti-viral compounds |
Dec, 2030
(7 years from now) | |
|
US9586978 (Pediatric) | ABBVIE INC | Anti-viral compounds |
May, 2031
(7 years from now) | |
|
US8648037 (Pediatric) | ABBVIE INC | Macrocyclic proline derived HCV serine protease inhibitors |
Jul, 2032
(8 years from now) | |
|
US8937150 (Pediatric) | ABBVIE INC | Anti-viral compounds |
Nov, 2032
(9 years from now) | |
| US11484534 | ABBVIE INC | Methods for treating HCV |
Mar, 2034
(10 years from now) | |
| US10286029 | ABBVIE INC | Method for treating HCV |
Mar, 2034
(10 years from now) | |
|
US10286029 (Pediatric) | ABBVIE INC | Method for treating HCV |
Sep, 2034
(10 years from now) | |
|
US11484534 (Pediatric) | ABBVIE INC | Methods for treating HCV |
Sep, 2034
(10 years from now) | |
|
USRE48923 (Pediatric) | ABBVIE INC | Crystal forms |
Nov, 2035
(12 years from now) | |
|
US9321807 (Pediatric) | ABBVIE INC | Crystal forms |
Dec, 2035
(12 years from now) | |
| US11246866 | ABBVIE INC | Solid pharmaceutical compositions for treating HCV |
Jun, 2036
(12 years from now) | |
|
US11246866 (Pediatric) | ABBVIE INC | Solid pharmaceutical compositions for treating HCV |
Dec, 2036
(13 years from now) | |
Mavyret is owned by Abbvie Inc.
Mavyret contains Glecaprevir; Pibrentasvir.
Mavyret has a total of 20 drug patents out of which 0 drug patents have expired.
Mavyret was authorised for market use on 03 August, 2017.
Mavyret is available in tablet;oral dosage forms.
Mavyret can be used as treatment of chronic hepatitis c virus (hcv) genotype 1, 2, 3, 4, 5, or 6 in adult and pediatric patients 12 years and older or weighing at least 45 kg, treatment of chronic hepatitis c virus (hcv) genotype 1, 2, 3, 4, 5, or 6 in pediatric patients 3 to less than 12 years of age or weighing less than 45 kg.
The generics of Mavyret are possible to be released after 24 December, 2036.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Jun 10, 2028 |
| M (M) | Apr 10, 2023 |
| Pediatric Exclusivity (PED) | Dec 10, 2028 |
Drugs and Companies using GLECAPREVIR; PIBRENTASVIR ingredient
Market Authorisation Date: 03 August, 2017
Treatment: Treatment of chronic hepatitis c virus (hcv) genotype 1, 2, 3, 4, 5, or 6 in pediatric patients 3 to less than 12 years of age or weighing less than 45 kg; Treatment of chronic hepatitis c virus (hcv)...
Dosage: TABLET;ORAL
MAVYRET family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic